Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer

Katerina Politi, Thomas J. Lynch

Clin Cancer Res (2012) 18 (6): 1490–1492.

https://doi.org/10.1158/1078-0432.CCR-11-3282

Published: 14 March 2012

View article titled, Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer

Includes: Supplementary data

Journal Articles

Integration of Molecular Profiling into the Lung Cancer Clinic

William Pao, Mark G. Kris, A. John Iafrate, Marc Ladanyi, Pasi A. Jänne, Ignacio I. Wistuba, Ryn Miake-Lye, Roy S. Herbst, David P. Carbone, Bruce E. Johnson, Thomas J. Lynch

Clin Cancer Res (2009) 15 (17): 5317–5322.

https://doi.org/10.1158/1078-0432.CCR-09-0913

Published: 31 August 2009

View article titled, Integration of Molecular Profiling into the Lung Cancer Clinic

Journal Articles

Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis

Penelope A. Bradbury, Rihong Zhai, Clement Ma, Wei Xu, Jessica Hopkins, Matthew J. Kulke, Kofi Asomaning, Zhaoxi Wang, Li Su, Rebecca S. Heist, Thomas J. Lynch, John C. Wain, David Christiani, Geoffrey Liu

Clin Cancer Res (2009) 15 (14): 4680–4685.

https://doi.org/10.1158/1078-0432.CCR-09-0192

Published: 15 July 2009

View article titled, Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis

Journal Articles

p53 Arg72Pro and MDM2 T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis

David W. Cescon, Penelope A. Bradbury, Kofi Asomaning, Jessica Hopkins, Rihong Zhai, Wei Zhou, Zhaoxi Wang, Matthew Kulke, Li Su, Clement Ma, Wei Xu, Ariela L. Marshall, Rebecca Suk Heist, John C. Wain, Thomas J. Lynch, Jr., David C. Christiani, Geoffrey Liu

Clin Cancer Res (2009) 15 (9): 3103–3109.

https://doi.org/10.1158/1078-0432.CCR-08-3120

Published: 30 April 2009

View article titled, p53 Arg72Pro and MDM2 T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis

Journal Articles

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski, Thomas J. Lynch, Pamela N. Munster, Geoffrey I. Shapiro, Pasi A. Jänne, Joseph P. Eder, Michael J. Naughton, Matthew J. Ellis, Suzanne F. Jones, Tarek Mekhail, Charles Zacharchuk, Jennifer Vermette, Richat Abbas, Susan Quinn, Christine Powell, Howard A. Burris

Clin Cancer Res (2009) 15 (7): 2552–2558.

https://doi.org/10.1158/1078-0432.CCR-08-1978

Published: 01 April 2009

View article titled, A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Journal Articles

Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors

Andrew X. Zhu, Neal Ready, Jeffrey W. Clark, Howard Safran, Antonino Amato, Nadia Salem, Silvia Pace, Xiaoying He, Nela Zvereva, Thomas J. Lynch, David P. Ryan, Jeffrey G. Supko

Clin Cancer Res (2009) 15 (1): 374–381.

https://doi.org/10.1158/1078-0432.CCR-08-1024

Published: 31 December 2008

View article titled, Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors

Journal Articles

Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment

Tan Min Chin, Margaret P. Quinlan, Anurag Singh, Lecia V. Sequist, Thomas J. Lynch, Daniel A. Haber, Sreenath V. Sharma, Jeffrey Settleman

Clin Cancer Res (2008) 14 (21): 6867–6876.

https://doi.org/10.1158/1078-0432.CCR-08-0093

Published: 03 November 2008

View article titled, Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment

Journal Articles

Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non–Small Cell Lung Cancer

Rihong Zhai, Geoffrey Liu, Wei Zhou, Li Su, Rebecca Suk Heist, Thomas J. Lynch, John C. Wain, Kofi Asomaning, Xihong Lin, David C. Christiani

Clin Cancer Res (2008) 14 (2): 612–617.

https://doi.org/10.1158/1078-0432.CCR-07-1655

Published: 25 January 2008

View article titled, Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non–Small Cell Lung Cancer

Journal Articles

Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

Thomas J. Lynch, Philip D. Bonomi, Charles Butts, Angela M. Davies, Jeffrey Engelman, Ramaswamy Govindan, Roy S. Herbst, John V. Heymach, Bruce E. Johnson, Renato G. Martins, Roman Perez-Soler, Gregory J. Riely, Alan B. Sandler, Lecia V. Sequist, Mark A. Socinski, Kwok-Kin Wong, Carol S. Hart

Clin Cancer Res (2007) 13 (15): 4583s–4588s.

https://doi.org/10.1158/1078-0432.CCR-07-0716

Published: 01 August 2007

View article titled, Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

Journal Articles

Second Hand Smoke Exposure and Survival in Early-Stage Non–Small-Cell Lung Cancer Patients

Wei Zhou, Rebecca S. Heist, Geoffrey Liu, Kofi Asomaning, David P. Miller, Donna S. Neuberg, John C. Wain, Thomas J. Lynch, David C. Christiani

Clin Cancer Res (2006) 12 (23): 7187–7193.

https://doi.org/10.1158/1078-0432.CCR-06-1460

Published: 04 December 2006

View article titled, Second Hand Smoke Exposure and Survival in Early-Stage Non–Small-Cell Lung Cancer Patients

Journal Articles

Matrix Metalloproteinase Polymorphisms and Survival in Stage I Non–Small Cell Lung Cancer

Rebecca Suk Heist, Ariela L. Marshall, Geoffrey Liu, Wei Zhou, Li Su, Donna Neuberg, Thomas J. Lynch, John Wain, David C. Christiani

Clin Cancer Res (2006) 12 (18): 5448–5453.

https://doi.org/10.1158/1078-0432.CCR-06-0262

Published: 25 September 2006

View article titled, Matrix Metalloproteinase Polymorphisms and Survival in Stage I Non–Small Cell Lung Cancer

Journal Articles

Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients

Lecia V. Sequist, Victoria A. Joshi, Pasi A. Jänne, Daphne W. Bell, Panos Fidias, Neal I. Lindeman, David N. Louis, Jeffrey C. Lee, Eugene J. Mark, Janina Longtine, Peter Verlander, Raju Kucherlapati, Matthew Meyerson, Daniel A. Haber, Bruce E. Johnson, Thomas J. Lynch

Clin Cancer Res (2006) 12 (14): 4403s–4408s.

https://doi.org/10.1158/1078-0432.CCR-06-0099

Published: 20 July 2006

View article titled, Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients

Journal Articles

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

Thomas J. Lynch, Alex A. Adjei, Paul A. Bunn, Jr., Tim G. Eisen, Jeffrey Engelman, Glenwood D. Goss, Daniel A. Haber, John V. Heymach, Pasi A. Jänne, Bruce E. Johnson, David H. Johnson, Rogerio C. Lilenbaum, Matthew Meyerson, Alan B. Sandler, Lecia V. Sequist, Jeffrey Settleman, Kwok-Kin Wong, Carol S. Hart

Clin Cancer Res (2006) 12 (14): 4365s–4371s.

https://doi.org/10.1158/1078-0432.CCR-06-1005

Published: 20 July 2006

View article titled, Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

Journal Articles

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

David M. Jackman, Beow Y. Yeap, Lecia V. Sequist, Neal Lindeman, Alison J. Holmes, Victoria A. Joshi, Daphne W. Bell, Mark S. Huberman, Balazs Halmos, Michael S. Rabin, Daniel A. Haber, Thomas J. Lynch, Matthew Meyerson, Bruce E. Johnson, Pasi A. Jänne

Clin Cancer Res (2006) 12 (13): 3908–3914.

https://doi.org/10.1158/1078-0432.CCR-06-0462

Published: 03 July 2006

View article titled, Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

Journal Articles

Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer: Predicting Clinical Response to Kinase Inhibitors

Lecia V. Sequist, Daniel A. Haber, Thomas J. Lynch

Clin Cancer Res (2005) 11 (16): 5668–5670.

https://doi.org/10.1158/1078-0432.CCR-05-1055

Published: 22 August 2005

View article titled, Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer: Predicting Clinical Response to Kinase Inhibitors

Journal Articles

Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement

Thomas J. Lynch, Jeffrey A. Bogart, Walter J. Curran, Jr, Malcolm M. DeCamp, David R. Gandara, Glenwood Goss, Claudia I. Henschke, James R. Jett, Bruce E. Johnson, Karen L. Kelly, Thierry Le Chevalier, James L. Mulshine, Giorgio V. Scagliotti, Joan H. Schiller, Alice Shaw, Nick Thatcher, Everett E. Vokes, Douglas E. Wood, Carol Hart

Clin Cancer Res (2005) 11 (13): 4981s–4983s.

https://doi.org/10.1158/1078-0432.CCR-05-9015

Published: 06 July 2005

View article titled, Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement

Journal Articles

Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer

John R. Goffin, Ian C. Anderson, Jeffrey G. Supko, Joseph Paul Eder, Jr., Geoffrey I. Shapiro, Thomas J. Lynch, Margaret Shipp, Bruce E. Johnson, Arthur T. Skarin

Clin Cancer Res (2005) 11 (9): 3417–3424.

https://doi.org/10.1158/1078-0432.CCR-04-2144

Published: 02 May 2005

View article titled, Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer

Journal Articles

Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non–Small Cell Lung Cancer Patients

Rebecca Suk, Sarada Gurubhagavatula, Sohee Park, Wei Zhou, Li Su, Thomas J. Lynch, John C. Wain, Donna Neuberg, Geoffrey Liu, David C. Christiani

Clin Cancer Res (2005) 11 (4): 1534–1538.

https://doi.org/10.1158/1078-0432.CCR-04-1953

Published: 02 March 2005

View article titled, Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non–Small Cell Lung Cancer Patients

Journal Articles

Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Wei Zhou, Sarada Gurubhagavatula, Geoffrey Liu, Sohee Park, Donna S. Neuberg, John C. Wain, Thomas J. Lynch, Li Su, David C. Christiani

Clin Cancer Res (2004) 10 (15): 4939–4943.

https://doi.org/10.1158/1078-0432.CCR-04-0247

Published: 05 August 2004

View article titled, Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Journal Articles

Novel Agents in the Treatment of Lung Cancer: Conference Summary Statement

Thomas J. Lynch, Alex A. Adjei, Paul A. Bunn, Jr., Raymond N. DuBois, David R. Gandara, Giuseppe Giaccone, Ramaswamy Govindan, Roy S. Herbst, Bruce E. Johnson, Fadlo R. Khuri, Roman Perez-Soler, Rafael Rosell, Eric K. Rowinsky, Alan B. Sandler, Giorgio V. Scagliotti, Joan H. Schiller, Geoffrey I. Shapiro, Mark A. Socinski, Carol S. Hart

Clin Cancer Res (2004) 10 (12): 4199s–4204s.

https://doi.org/10.1158/1078-0432.CCR-040021

Published: 15 June 2004

View article titled, Novel Agents in the Treatment of Lung Cancer: <subtitle>Conference Summary Statement</subtitle>

NARROW

Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer

Integration of Molecular Profiling into the Lung Cancer Clinic

Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis

p53 Arg72Pro and MDM2 T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors

Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment

Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non–Small Cell Lung Cancer

Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

Second Hand Smoke Exposure and Survival in Early-Stage Non–Small-Cell Lung Cancer Patients

Matrix Metalloproteinase Polymorphisms and Survival in Stage I Non–Small Cell Lung Cancer

Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer: Predicting Clinical Response to Kinase Inhibitors

Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement

Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer

Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non–Small Cell Lung Cancer Patients

Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

Novel Agents in the Treatment of Lung Cancer: Conference Summary Statement

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only